Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

Global single photon emission computed tomography (SPECT) market to reach $2.7 billion by the year 2027
News | SPECT Imaging
Global SPECT Market 2021 Research Report

July 7, 2021 — Amid the COVID-19 crisis, the global market for single photon emission computed tomography (SPECT) ...

Time July 07, 2021
arrow
The RefleXion X1 is the world’s first biology-guided radiotherapy (BgRT) machine that’s expected to improve treatment and expand options for patients with metastatic disease, where few treatments are currently available.
News | Radiation Therapy
UPMC Hillman Cancer Center Among First in Country to Offer Radiotherapy That Lets Tumors Guide Treatment

June 29, 2021 — UPMC Hillman Cancer Center will be the first cancer center in the eastern United States, and one of just ...

Time June 29, 2021
arrow
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
News | PET Imaging
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

Time June 28, 2021
arrow
GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.
News | Nuclear Imaging
GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

Time June 22, 2021
arrow
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67)

June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time June 22, 2021
arrow
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.
News | Prostate Cancer
PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

Time June 21, 2021
arrow
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.
News | PET Imaging
New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases ...

Time June 16, 2021
arrow
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame
News | PET Imaging
SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

June 16, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET) ...

Time June 16, 2021
arrow
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.
News | PET Imaging
New Super-resolution Technique Allows for More Detailed Brain Imaging

June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease ...

Time June 14, 2021
arrow
Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
News | PET-CT
Radiotracer Effective for Detection and Assessment of Lung Fibrosis

June 14, 2021 — Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) ...

Time June 14, 2021
arrow
Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.
News | SPECT Imaging
Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events

June 14, 2021 — An advanced artificial intelligence technique known as deep learning can predict major adverse cardiac ...

Time June 14, 2021
arrow
News | PET-CT
Canon Medical’s Digital PET/CT System Receives FDA Clearance

June 10, 2021 — Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ ...

Time June 10, 2021
arrow
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.
News | PET Imaging
FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm

June 7, 2021 — The U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) for the treatment of Alzheimer ...

Time June 07, 2021
arrow
Winship Cancer Institute of Emory University’s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint
News | Radiation Therapy
Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

May 25, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 25, 2021
arrow
According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary lymph node or ipsilateral deltoid uptake is occasionally observed on FDG or 11C-choline PET performed after Pfizer-BioNTech or Moderna COVID-19 vaccination
News | Coronavirus (COVID-19)
Nodal and Deltoid Radiotracer Uptake on Post-COVID-19 Vaccination PET

May 19, 2021 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary ...

Time May 19, 2021
arrow
Videos | Coronavirus (COVID-19)
VIDEO: COVID Vaccine Adenopathy Can Last Up to 10 Weeks

Yael Eshet, M.D., MSc, a diagnostic radiology specialist at Sheba Medical Center in Israel, was the lead author on a ...

Time May 11, 2021
arrow
GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18)
News | PET Imaging
GE Healthcare Acquires Zionexa

May 6, 2021 — GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology ...

Time May 06, 2021
arrow
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by
News | PET Imaging
PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

May 5, 2021 — For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable ...

Time May 05, 2021
arrow
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer
Feature | Radiation Oncology | By Vinay Shivaprasad
The Rise of Therapeutic Radiopharmaceuticals

The term nuclear medicine is associated with the diagnostic procedures single-photon emission computed tomography (SPECT ...

Time May 04, 2021
arrow
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

Time April 29, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now